Tambocor


Also found in: Dictionary, Medical, Wikipedia.
Related to Tambocor: flecainide, Concor
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for Tambocor

oral antiarrhythmic medication (trade name Tambocor) used as a last resort in treating arrhythmias

References in periodicals archive ?
In addition, Eisai has made special efforts, such as reducing the bitterness, to make Tambocor Fine Granules easy to administer.
Within two years, pharmacists were filling thousands of Tambocor prescriptions a month to treat irregular heartbeats.
Furthermore, Tambocor is the only sodium channel blocking agent in Japan to be approved for the treatment of tachyarrythmia in pediatric patients.
There are faint echoes of this experience in FDA's more recent approval of Tambocor (flecainide acetate), a drug intended to treat cardiac arrhythmias or irregular heart rhythms.
14 January 2010 - Japan-based pharmaceutical company Eisai Co Ltd announced today that it has submitted an application for approval of an additional indication of anti-arrhythmic agent Tambocor 50mg Tablets and Tambocor 100mg Tablets (generic name: flecainide acetate) for the treatment of tachyarrhythmia in paediatric patients in Japan.
Ranbaxy Laboratories received FDA approval for its generic version of 3M Pharmaceuticals' Tambocor.
Tambocor, Mexitil, Cardarone, Enkaid, Decabid Anticonvulsants - Dilantin, phenobarbital, Tegretol, Depakene/
Tambocor (cardiac arrhythmia treatment) amounted to SEK 921 million (901), a 2% increase on the previous year.
3M markets flecainide acetate tablets under the brand name Tambocor.
Tambocor (cardiac arrhythmia treatment) reached SEK 712 million (670), a 6% increase on the previous year.
Over the next few years the company expects to launch first-to-file generic versions of a number of market leaders, include Prilosec (omeprazole), Xalatan (latanprost), Tambocor (flecanide), Paxil (paroxetine hydrochloride) and Zyprexa (olanzapine).
Tambocor (cardiac arrhythmia treatment) reached SEK 484 million (473), a 2% increase on the previous year.
Late last month it initiated a challenge of the raw material patents protecting 3M Pharmaceuticals' Tambocor tablets from generic competition.
Tambocor (cardiac arrhythmia treatment) climbed to SEK 236 million (230), a 3% increase on Q1 2008.
Earlier this year Barr challenged the patent protecting the raw materials used in 3M Pharmaceuticals' heart drug Tambocor from generics competition; and it also challenged the patents protecting Ortho-McNeil Pharmaceutical Inc.